Neuroinflammatory paradigms in lysosomal storage diseases

Нейровоспалительные парадигмы при лизосомных болезнях накопления
Tammy Kielian, Megan E. Bosch
2015-10-30

astrocyte activationlysosomal storage diseasesmicroglial activationneurodegenerationneuroinflammation
Lysosomal storage diseases (LSDs) include approximately 70 distinct disorders that collectively account for 14% of all inherited metabolic diseases. LSDs are caused by mutations in various enzymes/proteins that disrupt lysosomal function, which impairs macromolecule degradation following endosome-lysosome and phagosome-lysosome fusion and autophagy, ultimately disrupting cellular homeostasis. LSDs are pathologically typified by lysosomal inclusions composed of a heterogeneous mixture of various proteins and lipids that can be found throughout the body. However, in many cases the CNS is dramatically affected, which may result from heightened neuronal vulnerability based on their post-mitotic state. Besides intrinsic neuronal defects, another emerging factor common to many LSDs is neuroinflammation, which may negatively impact neuronal survival and contribute to neurodegeneration. Microglial and astrocyte activation is a hallmark of many LSDs that affect the CNS, which often precedes and predicts regions where eventual neuron loss will occur. However, the timing, intensity, and duration of neuroinflammation may ultimately dictate the impact on CNS homeostasis. For example, a transient inflammatory response following CNS insult/injury can be neuroprotective, as glial cells attempt to remove the insult and provide trophic support to neurons. However, chronic inflammation, as seen in several LSDs, can promote neurodegeneration by creating a neurotoxic environment due to elevated levels of cytokines, chemokines, and pro-apoptotic molecules. Although neuroinflammation has been reported in several LSDs, the cellular basis and mechanisms responsible for eliciting neuroinflammatory pathways are just beginning to be defined. This review highlights the role of neuroinflammation in select LSDs and its potential contribution to neuron loss.
1
Central nervous system involvement is common in many lysosomal storage diseases, likely reflecting heightened vulnerability of post-mitotic neurons alongside intrinsic neuronal defects.
2
Lysosomal storage diseases comprise approximately 70 disorders and 14% of inherited metabolic diseases, arising from mutations that disrupt lysosomal degradation and cellular homeostasis.
3
Microglial and astrocyte activation is a hallmark of CNS-affected lysosomal storage diseases and often precedes and predicts regions of subsequent neuronal loss.
4
The cellular mechanisms initiating neuroinflammatory pathways in lysosomal storage diseases remain incompletely defined, although neuroinflammation is increasingly implicated in neuron loss.
5
The effects of neuroinflammation depend on its timing, intensity, and duration: transient responses may be neuroprotective, whereas chronic inflammation can create a neurotoxic environment that promotes neurodegeneration.

central nervous system involvement in lysosomal storage diseases

the cellular mechanisms, temporal characteristics, and neurodegenerative consequences of neuroinflammation, including microglial and astrocyte activation

Publication Details
Publication Date
2015-10-30
Journal
Publisher
ISSN
Cited by
140
Access Type
Author Information
Authors
Tammy Kielian
Megan E. Bosch
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%